Diane Wang, Ph.D.

Diane Wang, Ph.D., is Senior Vice President of Clinical Pharmacology and Preclinical Development at BlossomHill Therapeutics. With over 30 years of experience in drug development as a clinical pharmacologist and regulatory scientist, Dr. Wang brings extensive expertise to her role. Before joining BlossomHill, she was an Executive Director at Pfizer Oncology, where she spent over 20 years leading a team of clinical pharmacologists and made key contributions to the development, submission, and approval of several new molecular entities (NMEs), including Ibrance^®, Talzenna^®, Elrexfio^®, and Sutent^®. She also spearheaded numerous early-phase programs, conducting first-in-human (FIH) trials and establishing proof-of-mechanism (POM) and proof-of-concept (POC). Earlier in her career, Dr. Wang held positions at Amgen and Immunex, focusing primarily on biologics development. Prior to her industry roles, she served as a Senior Clinical Pharmacology/Pharmacometrics Reviewer at the FDA’s Office of Clinical Pharmacology, where she reviewed numerous INDs and NDAs and contributed to the development of regulatory guidance. Dr. Wang has over 50 peer-reviewed papers/book chapters and is a frequent speaker at leading clinical pharmacology conferences.

Dr. Wang received her Ph.D. in Pharmaceutical Sciences from the Medical University of South Carolina. Her research interests include model-informed drug development, dose optimization for oncology drugs, dosing strategies for biologics, and accelerated drug development in East Asian countries.